-- パシフィック・シュアンリン・バイオファーマシー（SHE:000403）傘下の広東シュアンリンは、ヒトトロンビンの臨床試験承認を中国医薬品規制当局から取得した。 深セン証券取引所への月曜日の提出書類によると、この薬剤は、標準的な止血法が奏功しない場合の、手術中の毛細血管および細静脈からの出血に対する補助的な止血剤として使用される予定である。 同社の株価は月曜日、1%下落して取引を終えた。
Related Articles
Asia
Hunan Gold Q1 Profit Up 79%, Revenue Climbs 44%
Hunan Gold (SHE:002155) posted first-quarter attributable net profit of 595.5 million yuan, up 79% from 332.3 million yuan the previous year.Earnings per share went up to 0.38 yuan from 0.21 yuan, according to a weekend filing with the Shenzhen bourse.Operating revenue climbed 44% year over year to 18.8 billion yuan from 13.1 billion yuan.Shares of the miner declined 2% in recent trade.
$SHE:002155
International
Singapore Manufacturing Output Rises 10% in March
Singapore's manufacturing output jumped 10.1% in March, backed by strong growth across almost all clusters, the city-state's Department of Statistics reported Monday.Excluding biomedical manufacturing, output rose 13.5% year-on-year in March.Electronics output grew 30%, driven by robust AI-related demand, the data showed. Precision engineering gained 14.0%, while general manufacturing and transport engineering expanded 7.6% and 2.0%, respectively.Meanwhile, biomedical manufacturing fell 14.3%, mainly due to softer demand for medical devices, while chemicals dropped 16.0%.On a month-on-month basis, manufacturing output increased 4.7% in March. Excluding biomedical manufacturing, output was up 3.5% on a monthly basis.
$^STI
Asia
G8 Education Says Macquarie Group Becomes Substantial Holder
G8 Education (ASX:GEM) said Macquarie Group (ASX:MQG) became a substantial holder on April 22 after acquiring 39.2 million securities of the firm, according to a Monday Australian bourse filing.Macquarie's voting power in the firm is now 5.08%.Its shares were up over 1% in recent trading on Monday.
$ASX:GEM$ASX:MQG